Last reviewed · How we verify
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief
3 marketed
0 filed
1 Phase 3
3 Phase 2
8 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Hemoporfin | Hemoporfin | marketed | Other | |||
| Doxorubicin hydrochloride liposome | Doxorubicin hydrochloride liposome | marketed | Anthracycline chemotherapy agent (liposomal formulation) | DNA topoisomerase II | Oncology | |
| Hemoporfin PDT | Hemoporfin PDT | marketed | Photosensitizer | Porphyrin-based photosensitizer (non-receptor mediated) | Oncology | |
| FDA018-ADC | FDA018-ADC | phase 3 | Antibody-drug conjugate (ADC) | Oncology |
Therapeutic area mix
- Oncology · 5
- Other · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- AstraZeneca · 1 shared drug class
- BioAtla, Inc. · 1 shared drug class
- Byondis B.V. · 1 shared drug class
- Charite University, Berlin, Germany · 1 shared drug class
- Gustave Roussy, Cancer Campus, Grand Paris · 1 shared drug class
- Jiaxing AnDiCon Biotech Co.,Ltd · 1 shared drug class
- Amgen · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.:
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. pipeline updates — RSS
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. pipeline updates — Atom
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shanghai-fudan-zhangjiang-bio-pharmaceutical-co-ltd. Accessed 2026-05-17.